Contrasting roles of donor and recipient TGFB1 and IFNG gene polymorphic variants in chronic kidney transplant rejection.

Einstein (Sao Paulo) 2011 Mar;9(1):46-51

Instituto de Investigação em Imunologia, Institutos Nacionais de Ciência e Tecnologia, BR.

Objective: To assess the long-term impact (minimum of 3 years follow-up) of polymorphisms in cytokine genes in donor:recipient pairs on the results of the transplant.

Methods: We compared genetic cytokine polymorphisms and the primary factors of risk for the development of chronic rejection in paired groups of renal transplant patients with and without chronic allograft nephropathy [CAN].

Results: Multivariate analysis indicated that the presence of the high-production TT genotype (codon 10) of the transforming growth factor beta-1 (TGFB1) was protective in receptors (p=0.017), contrasting with the increased risk when present in donor samples (p=0.049). On the other hand, in the case of the gamma interferon studied, the greater frequency of the high production allele was protective in the analysis of the donor group (p=0.013), increasing the risk of chronic nephropathy of the allograft when present in the recipients (p=0.036).

Conclusion: Our results highlight the importance of TGFB1 genotyping in donors, and indicate that polymorphisms in the gene of this cytokine in donor cells might contribute to the development of chronic allograft nephropathy.

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1679-45082011AO1852DOI Listing
March 2011
Get 20% Off Journals at LWW.com

Similar Publications

Post-mortem molecular investigations of SARS-CoV-2 in an unexpected death of a recent kidney transplant recipient.

Am J Transplant 2021 Feb 24. Epub 2021 Feb 24.

Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Solid organ transplant recipients are vulnerable to severe infection during induction therapy. We report a case of a 67-year-old male who died unexpectedly 10 days after receiving a kidney transplant on February 10, 2020. There was no clear cause of death, but COVID-19 was considered retrospectively, as the death occurred shortly after the first confirmed case of COVID-19 in Canada. Read More

View Article and Full-Text PDF
February 2021

Prevalence and Predictors of SARS-CoV-2 Antibodies among Solid Organ Transplant Recipients with Confirmed Infection.

Am J Transplant 2021 Feb 16. Epub 2021 Feb 16.

Center for Liver Disease and Transplantation, Columbia University College of Physicians & Surgeons, New York, NY, USA.

It remains uncertain whether immunocompromised patients including solid organ transplant (SOT) recipients will have a robust antibody response to SARS-CoV-2 infection. We enrolled all adult SOT recipients at our center with confirmed SARS-CoV-2 infection who underwent antibody testing with a single commercially available anti-nucleocapsid antibody test at least 7 days after diagnosis in a retrospective cohort. 70 SOT recipients were studied (56% kidney, 19% lung, 14% liver +/- kidney, and 11% heart +/- kidney recipients). Read More

View Article and Full-Text PDF
February 2021

Thrombotic microangiopathy in a renal allograft: Single-center five-year experience.

Saudi J Kidney Dis Transpl 2020 Nov-Dec;31(6):1331-1343

Department of Biostatistics, G. R. Doshi and K. M. Mehta Institute of Kidney Diseases and Research Centre and Dr. H. L. Trivedi Institute of Transplantation Sciences, Civil Hospital-Medicity Campus, Asarwa, Ahmedabad, India.

Thrombotic microangiopathy (TMA) is devastating for renal transplantation (RT) causing graft/ patient loss. We present 5-year experience of TMA in RT in retrospective study of indicated renal allograft biopsies with TMA. Patient-donor demographics and associated histological findings with respect to transplants under tolerance induction protocol (Group 1) were compared with patients transplanted under triple immunosuppression (Group 2). Read More

View Article and Full-Text PDF
February 2021

Acute renal transplant rejection following nivolumab therapy for metastatic melanoma.

BMJ Case Rep 2021 Feb 8;14(2). Epub 2021 Feb 8.

Tayside Cancer Centre, Ninewells Hospital, Dundee, Dundee, UK.

Cancers can develop the ability to evade immune recognition and destruction. Immune checkpoint inhibitors (ICIs) are drugs targeting these immune evasion mechanisms. ICIs have significantly improved outcomes in several cancers including metastatic melanoma. Read More

View Article and Full-Text PDF
February 2021

NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant development.

EMBO Mol Med 2021 Feb 8:e12834. Epub 2021 Feb 8.

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, China.

Herein, we demonstrate that NFAT, a key regulator of the immune response, translocates from cytoplasm to nucleolus and interacts with NF45/NF90 complex to collaboratively promote rDNA transcription via triggering the directly binding of NF45/NF90 to the ARRE2-like sequences in rDNA promoter upon T-cell activation in vitro. The elevated pre-rRNA level of T cells is also observed in both mouse heart or skin transplantation models and in kidney transplanted patients. Importantly, T-cell activation can be significantly suppressed by inhibiting NF45/NF90-dependent rDNA transcription. Read More

View Article and Full-Text PDF
February 2021